In Group 2, four out of 174 participants with neoplasms carried variants in BRCA2 (rs768580992, review status “reviewed by expert panel”) and MUTYH (rs36053993, rs36053993, and rs34612342; review status “multiple submitters”). This evidence concerns the gene BRCA2 and neoplasm.